Fasting Exacerbates Acute Pancreatitis by Occlusion of the Common Bile Duct in Rats
スポンサーリンク
概要
- 論文の詳細を見る
We examined the effects of fasting and non-fasting on gallstone-related acute pancreatitis by the occlusion of the common bile duct (OCD). We prepared a rat OCD-induced pancreatitis model under both fasting and non-fasting conditions, and we measured amylase activity in ascites as well as production of inflammatory cytokines and chemokines. We also examined the pathology of the pancreas, myeloperoxidase (MPO) activity in some tissues and mortality rates. In the fasted OCD group, ascites containing a large amount of amylase, interleukin 1β (IL-1β), interleukin 6 (IL-6), and cytokine-induced neutrophil chemoattractant-1 (CINC-1) as well as marked hemorrhage and necrosis of the pancreatic acinar cells were observed. Pulmonary MPO activity increased 3.4-fold compared to the control group. In the non-fasted OCD group, there was no development of ascites. Slight necrosis of acinar cells and slight increases in pulmonary MPO activity were observed. In addition, in the fasted OCD group, the cumulative mortality rate was 50% 6 days after ligation. However, in the non-fasted OCD group, none of the animals died. These results suggest that gallstone-related severe pancreatitis depends on fasting-related structural and/or functional changes in the pancreas. Moreover, increased production of inflammatory cytokines and chemokines in ascites under fasting condition may be involved in multiple organ failure resulting from severe acute pancreatitis.
- 社団法人 日本薬理学会の論文
- 2000-12-01
著者
-
Yoshinaga Koji
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Yoshinaga Koji
Central Res. Laboratories Zeria Pharmaceutical Co. Ltd.
-
Yoshinaga Koji
Central Research Laboratories Zeria Pharmaceutical Co. Ltd
-
SEGAWA Yoshihide
Zeria Pharmaceutical Co., Ltd.
-
Segawa Y
Zeria Pharmaceutical Co. Ltd.
-
WASHIZUKA Masataka
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd
-
SEGAWA Yoshihide
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd
-
Washizuka Masataka
Central Research Laboratories Zeria Pharmaceutical Co. Ltd
関連論文
- Pharmacological Evaluation of Analgesic Effects of the Cholecystokinin2 Receptor Antagonist Z-360 in Mouse Models of Formalin- and Cancer-Induced Pain
- Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Augments Anti-tumor Activities of X-Ray Irradiation against B16 Melanoma in Association with the Improvement of Type 1T Cell Responses(Miscellaneous)
- Antimetastatic Effect of an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Z-100, through the Production of Interleukin-12(Miscellaneous)
- Anti-Tumor Mechanism of Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, on Pulmonary Metastases of B16F10 Melanoma : Restoration of Helper T Cell Responses via Suppression of Glucocorticoid-Genesis
- Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
- Possible Changes in Expression of Chemotaxin LECT2 mRNA in Mouse Liver after Concanavalin A-Induced Hepatic Injury
- D-Galactosamine-Induced Mouse Hepatic Apoptosis : Possible Involvement with Tumor Necrosis Factor, but not with Caspase-3-Activity
- Fasting Exacerbates Acute Pancreatitis by Occlusion of the Common Bile Duct in Rats
- Diet Stimulation as a Synergistic Factor of Aggravation in a Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model
- Cholecystokinin Acts as an Essential Factor in the Exacerbation of Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model Under Non-fasting Condition